I consider it a distinct privilege to serve the patients and families that come to Boston Children’s, hearing and entering into their stories at some of the most profound moments in their lives.

EDUCATION

Undergraduate Degree

  • Northwestern University Medical School , 1980 , Chicago , IL

Medical School

  • Northwestern University Medical School , 1982 , Chicago , IL

Internship

  • University of California Medical Center , 1983 , San Diego , CA

Residency

  • University of California Medical Center , 1985 , San Diego , CA

Fellowship

Dysmorphology/Genetics
  • University of California Medical Center , 1987 , San Diego , CA

Fellowship

Cardiology
  • Boston Children's Hospital , 1991 , Boston , MA

Philosophy of Care

I grew up in Hawaii and attended college and medical school at Northwestern University in Evanston and Chicago, IL. I completed a residency in pediatrics as well as a fellowship in dysmorphology and genetics in San Diego, before moving to Boston for a fellowship in cardiology at Boston Children’s Hospital.  I joined the staff at Boston Children’s Hospital in 1991, specializing in cardiovascular genetics and echocardiography.

Boston has been my home since 1987, and I enjoy everything that the region has to offer, including the cardiology team at Boston Children’s Hospital.  I consider it a distinct privilege to serve the patients and families that come to Boston Children’s, hearing and entering into their stories at some of the most profound moments in their lives.

PROFESSIONAL HISTORY

Dr. Lacro is clinically trained in dysmorphology/clinical genetics as well as pediatric cardiology.  He directs the Cardiovascular Genetics Clinic and the Marfan Syndrome and Related Disorders Program, which provide cardiac and genetic services to patients and families with a variety of genetic conditions including Marfan syndrome, other connective tissue disorders, bicuspid aortic valve and other aortopathies, and Williams syndrome.  Dr. Lacro is on the staff of the Echocardiography Laboratory, which provides a full range of imaging studies including transesophageal and fetal examinations.  He was a Schwartz Center Fellow in Pastoral Care in 2002 and has an interest in spiritual assessment and spiritual care.  Research interests include pathogenesis of congenital cardiovascular malformations and management of patients with multiple malformation syndromes such as Marfan syndrome, other connective tissue disorders, and Williams syndrome.  Dr. Lacro was a principal investigator for a multicenter, randomized clinical trial sponsored by the Pediatric Heart Network and the National Heart, Lung, and Blood Institute of the NIH, comparing beta blocker therapy (atenolol) and angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.

CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Pediatric Cardiology
  • American Board of Genetics and Genomics

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Growth, development, and phenotypic spectrum of individuals with deletions of 2q33.1 involving SATB2. Clin Genet. 2021 04; 99(4):547-557. View abstract
  2. Effect of Losartan or Atenolol on Children and Young Adults With Bicuspid Aortic Valve and Dilated Aorta. Am J Cardiol. 2021 04 01; 144:111-117. View abstract
  3. Recruitment, retention, and adherence in a clinical trial: The Pediatric Heart Network's Marfan Trial experience. Clin Trials. 2020 12; 17(6):684-695. View abstract
  4. Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. J Pediatr. 2020 07; 222:213-220.e5. View abstract
  5. Genome Sequencing Identifies the Pathogenic Variant Missed by Prior Testing in an Infant with Marfan Syndrome. J Pediatr. 2019 10; 213:235-240. View abstract
  6. Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association. Circulation. 2018 11 20; 138(21):e653-e711. View abstract
  7. Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. J Pediatr. 2019 01; 204:250-255.e1. View abstract
  8. Three-Dimensional Mitral Valve Morphology in Children and Young Adults With Marfan Syndrome. J Am Soc Echocardiogr. 2018 11; 31(11):1168-1177.e1. View abstract
  9. Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome. Am J Cardiol. 2018 10 15; 122(8):1429-1436. View abstract
  10. Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome. Pediatr Cardiol. 2018 Oct; 39(7):1453-1461. View abstract
  11. Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome. Am J Cardiol. 2018 05 01; 121(9):1094-1101. View abstract
  12. Longitudinal Changes in Segmental Aortic Stiffness Determined by Cardiac Magnetic Resonance in Children and Young Adults With Connective Tissue Disorders (the Marfan, Loeys-Dietz, and Ehlers-Danlos Syndromes, and Nonspecific Connective Tissue Disorders). Am J Cardiol. 2017 Oct 01; 120(7):1214-1219. View abstract
  13. Response to Letters Regarding Article "Segmental Aortic Stiffness in Children and Young Adults With Connective Tissue Disorders: Relationships With Age, Aortic Size, Rate of Dilation, and Surgical Root Replacement". Circulation. 2016 Feb 16; 133(7):e405. View abstract
  14. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications. Can J Cardiol. 2016 Jan; 32(1):66-77. View abstract
  15. Segmental Aortic Stiffness in Children and Young Adults With Connective Tissue Disorders: Relationships With Age, Aortic Size, Rate of Dilation, and Surgical Root Replacement. Circulation. 2015 Aug 18; 132(7):595-602. View abstract
  16. Performant Mutation Identification Using Targeted Next-Generation Sequencing of 14 Thoracic Aortic Aneurysm Genes. Hum Mutat. 2015 Aug; 36(8):808-14. View abstract
  17. Clinical utility of a next generation sequencing panel assay for Marfan and Marfan-like syndromes featuring aortopathy. . 2015 Aug; 167A(8):1747-57. View abstract
  18. Children with Thoracic Aortic Aneurysm: Challenges in Diagnosis and Therapy. J Pediatr. 2015 Jul; 167(1):14-6. View abstract
  19. Atenolol versus Losartan in Marfan's Syndrome. N Engl J Med. 2015 03 05; 372(10):980-1. View abstract
  20. Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration. Am Heart J. 2015 May; 169(5):605-12. View abstract
  21. MATR3 disruption in human and mouse associated with bicuspid aortic valve, aortic coarctation and patent ductus arteriosus. Hum Mol Genet. 2015 Apr 15; 24(8):2375-89. View abstract
  22. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014 Nov 27; 371(22):2061-71. View abstract
  23. Arterial tortuosity in patients with Filamin A- associated vascular aneurysms. . 2014 Nov; 164A(11):2961-3. View abstract
  24. Cardiovascular disease in Noonan syndrome. Arch Dis Child. 2014 Jul; 99(7):629-34. View abstract
  25. Outcomes after primary transcatheter therapy in infants and young children with severe bilateral peripheral pulmonary artery stenosis. Circ Cardiovasc Interv. 2013 Aug; 6(4):460-7. View abstract
  26. Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome. J Am Soc Echocardiogr. 2013 Jun; 26(6):657-66. View abstract
  27. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J. 2013 May; 165(5):828-835.e3. View abstract
  28. Thoracic aortic disease in two patients with juvenile polyposis syndrome and SMAD4 mutations. Am J Med Genet A. 2013 Jan; 161A(1):185-91. View abstract
  29. Bicuspid aortic valve and associated aortic dilation in the young. Heart. 2012 Jul; 98(13):1014-9. View abstract
  30. Dilation of the ascending aorta after balloon valvuloplasty for aortic stenosis during infancy and childhood. Am J Cardiol. 2012 Sep 01; 110(5):702-8. View abstract
  31. Challenges in echocardiographic assessment of mitral regurgitation in children after repair of atrioventricular septal defect. Pediatr Cardiol. 2012 Feb; 33(2):205-14. View abstract
  32. Surgical interventions for atrioventricular septal defect subtypes: the pediatric heart network experience. Ann Thorac Surg. 2011 Oct; 92(4):1468-75; discussion 1475. View abstract
  33. Applying massive parallel sequencing to molecular diagnosis of Marfan and Loeys-Dietz syndromes. Hum Mutat. 2011 Sep; 32(9):1053-62. View abstract
  34. Increased vertebral artery tortuosity index is associated with adverse outcomes in children and young adults with connective tissue disorders. Circulation. 2011 Jul 26; 124(4):388-96. View abstract
  35. Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study. Am Heart J. 2011 Feb; 161(2):233-40. View abstract
  36. Potocki-Lupski syndrome: an inherited dup(17)(p11.2p11.2) with hypoplastic left heart. . 2011 Feb; 155A(2):367-71. View abstract
  37. Surgical management of complete atrioventricular septal defect: associations with surgical technique, age, and trisomy 21. J Thorac Cardiovasc Surg. 2011 Jun; 141(6):1371-9. View abstract
  38. Partial and transitional atrioventricular septal defect outcomes. Ann Thorac Surg. 2010 Feb; 89(2):530-6. View abstract
  39. Ascending aortic dilation in patients with congenital complete heart block. Heart Rhythm. 2008 Dec; 5(12):1704-8. View abstract
  40. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007 Dec; 120(6):1260-9. View abstract
  41. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007 Oct; 154(4):624-31. View abstract
  42. Measurement of technical performance in congenital heart surgery: a pilot study. Ann Thorac Surg. 2007 Jan; 83(1):179-84. View abstract
  43. Improved outcome with composite graft versus homograft root replacement for children with aortic root aneurysms. Eur J Cardiothorac Surg. 2005 Mar; 27(3):420-4. View abstract
  44. Fetal pulmonary artery diameters and their association with lung hypoplasia and postnatal outcome in congenital diaphragmatic hernia. Am J Obstet Gynecol. 2002 May; 186(5):1085-90. View abstract
  45. Heart size on chest x-ray as a predictor of cardiac enlargement by echocardiography in children. Pediatr Cardiol. 2001 May-Jun; 22(3):218-22. View abstract
  46. Fetal cardiac dextroposition in the absence of an intrathoracic mass: sign of significant right lung hypoplasia. J Ultrasound Med. 2000 Oct; 19(10):669-76. View abstract
  47. Cardiovascular malformations: changes in prevalence and birth status, 1972-1990. Am J Med Genet. 1999 May 21; 84(2):102-10. View abstract
  48. Adams-Oliver syndrome associated with cardiovascular malformations. Clin Dysmorphol. 1998 Oct; 7(4):235-41. View abstract
  49. Sudden death in Williams syndrome: report of ten cases. J Pediatr. 1996 Dec; 129(6):926-31. View abstract
  50. Clinical approach to genetic cardiomyopathy in children. Circulation. 1996 Oct 15; 94(8):2021-38. View abstract
  51. Renal findings in 40 individuals with Williams syndrome. Am J Med Genet. 1993 May 15; 46(3):271-4. View abstract
  52. Purification, characterization, and molecular cloning of a 60-kDa phosphoprotein in rabbit skeletal sarcoplasmic reticulum which is an isoform of phosphoglucomutase. J Biol Chem. 1992 Oct 15; 267(29):21080-8. View abstract
  53. Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest. 1992 Sep; 90(3):927-35. View abstract
  54. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med. 1989 Jun 22; 320(25):1661-6. View abstract
  55. Coarctation of the aorta in Turner syndrome: a pathologic study of fetuses with nuchal cystic hygromas, hydrops fetalis, and female genitalia. Pediatrics. 1988 Mar; 81(3):445-51. View abstract
  56. [Brachmann-de Lange syndrome: report of 4 cases in Mexican children]. Bol Med Hosp Infant Mex. 1987 Dec; 44(12):766-70. View abstract
  57. The Gorlin syndrome: a genetically determined disorder associated with cardiac tumor. J Thorac Cardiovasc Surg. 1987 Dec; 94(6):919-20. View abstract
  58. The umbilical cord twist: origin, direction, and relevance. Am J Obstet Gynecol. 1987 Oct; 157(4 Pt 1):833-8. View abstract
  59. X-linked laterality sequence: situs inversus, complex cardiac defects, splenic defects. Am J Med Genet. 1987 Sep; 28(1):111-6. View abstract
  60. New autosomal dominant branchio-oculo-facial syndrome. Am J Med Genet. 1987 Aug; 27(4):943-51. View abstract
  61. Duplication of distal 15q: report of five new cases from two different translocation kindreds. Am J Med Genet. 1987 Mar; 26(3):719-28. View abstract
  62. Hemorrhagic infarction and coronary reperfusion. J Thorac Cardiovasc Surg. 1981 Apr; 81(4):498-501. View abstract